San Diego biotech startup Gallant just raised $18 million in a Series B financing round, furthering its quest to deliver the first ready-to-use stem cell therapy through conditional U.S. Food and Drug Administration approval. But the company isn't directing those funds toward the treatment of sick humans. Rather, it's wants their high-tech research and development to cure multiple dog and cat diseases.
Health-focused investment firm Digitalis Ventures led the latest funding round, along with BOLD Capital and Hill Creek Partners. NovaQuest Capital Management joined as a new investor. This follows a successful $15 million Series A round completed in January 2024.
